Novel Strategies in The Treatment of Life-Threatening Diseases: Focus on Harlequin Ichthyosis

Harlequin Ichthyosis (HI) is a rare, life-threatening genetic disorder caused by mutations in the ABCA12 gene, leading to severe skin abnormalities, dehydration, and infection risk. Current treatments focus on supportive care, including topical emollients, systemic retinoids, and neonatal intensive care, which have improved survival but remain palliative rather than curative. Advances in genetic and molecular research offer promising novel strategies, such as CRISPR-Cas9 gene editing, stem cell therapy, targeted drug treatments, and innovative drug delivery systems. These approaches aim to correct the underlying genetic defect, enhance lipid transport, and improve skin barrier function. However, challenges persist, including treatment accessibility, ethical considerations, and long-term safety concerns. Overcoming these hurdles requires a multidisciplinary approach integrating genetics, bioengineering, and pharmacology. With continued research and policy reforms, transformative therapies may shift HI treatment from symptomatic management to curative solutions, improving survival rates and quality of life for affected individuals.